uncertainties' -to reflect the emphasis on value, not quantitative, judgements, which are required of regulatory groups. As an example of PNS applied to human research, the decision stakes (added risk) for a highly toxic intervention that is first undergoing testing would be higher for healthy people than for patients who have the condition under investigation. In this example, the system uncertainties (uncertainty about the occurrence of added risk) are similar for both groups.
However, the system uncertainties would be higher, say, if a procedure such as cardiac catheterization in healthy people was to be performed by a physician with little experience, compared with one with a highly successful track record. (The decision stakes, added risk, would be similar.)
Under the PNS approach, research administrators and IRB members would assess both criteria to allocate proposed research to one of three separate risk domains, which demand different levels of scrutiny and regulation. PNS designates the lowest of these domains as 'applied science' . Research currently typically categorized as exempt or expedited has relatively low decision stakes and low system uncertainty and would fall into this domain in which the principal investigator is given the responsibility to carry out the work with minimal oversight.
As levels of decision stakes and system uncertainty rise to intermediate, proposals are placed in the second category, which in PNS is called professional consultancy. This is the domain of ongoing involvement of IRBs and the increasing importance of participant understanding of the research to give informed consent. PNS use of separate criteria would lead to clearer analysis of what makes a project more or less risky, and help IRBs to reach decisions.
The final category, the domain of 'post-normal science' , is reserved for projects for which system uncertainties are so high that they include the adequacy of the current ethical principles used to assess risk. Values, in other words, become as important as facts. Managing risk in this zone needs extended consultation with a wider community, and one that assesses social values as well as scientific facts and expertise. A recent example of science that falls into this top tier is the question of whether or not to genetically engineer human embryos.
Using PNS to assess risk in human research has received little attention so far. But it offers a more coherent approach and permits a more nuanced analysis than the current regulatory framework. It would promote the goal of risk-based regulation of human research. ■ WORLD VIEWA personal take on events
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